Abstract
We have analyzed several members of drug-metabolizing enzymes (DMEs) and other polymorphisms in genes implicated in tumor aggressivity regarding possible links between specific genetic variability in systemic drug bioavailability and toxicity in breast cancer patients treated with adjuvant anthracycline-based treatment. PCR-RFLP and sequencing analyses technique were used for evaluating fourteen previously identified polymorphisms in 94 patients. GSTP1A > G and MTHFR 1298A > C genotypes remained as significant predictors in a multivariate logistic regression analysis. GSTP1 polymorphism was linked to haematological GIII-IV toxicity (P = 0.044, HR= 6.4, 95% CI = 1.05 to 39. Increased and significant HR was obtained for MTHFR-1298 AC+CC group when non-haematological toxicities GIII-IV toxicities were evaluated (HR = 24; 95% CI = 2.3 to 254), P = 0.008. Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline- based treatment of breast cancer.
Keywords: Anthracycline, breast cancer, drug-metabolizing enzymes, GSTP1, MTHFR, polymorphisms
Current Drug Metabolism
Title: GSTP1 and MTHFR Polymorphisms Are Related with Toxicity in Breast Cancer Adjuvant Anthracycline-Based Treatment
Volume: 8 Issue: 5
Author(s): R. Zarate, S. Gonzalez-Santiago, E. Bandres, R. Morales, J. Salgado, A. Gomez, E. Aranda and J. Garcia-Foncillas
Affiliation:
Keywords: Anthracycline, breast cancer, drug-metabolizing enzymes, GSTP1, MTHFR, polymorphisms
Abstract: We have analyzed several members of drug-metabolizing enzymes (DMEs) and other polymorphisms in genes implicated in tumor aggressivity regarding possible links between specific genetic variability in systemic drug bioavailability and toxicity in breast cancer patients treated with adjuvant anthracycline-based treatment. PCR-RFLP and sequencing analyses technique were used for evaluating fourteen previously identified polymorphisms in 94 patients. GSTP1A > G and MTHFR 1298A > C genotypes remained as significant predictors in a multivariate logistic regression analysis. GSTP1 polymorphism was linked to haematological GIII-IV toxicity (P = 0.044, HR= 6.4, 95% CI = 1.05 to 39. Increased and significant HR was obtained for MTHFR-1298 AC+CC group when non-haematological toxicities GIII-IV toxicities were evaluated (HR = 24; 95% CI = 2.3 to 254), P = 0.008. Our results suggest that GSTP1 and MTHFR genotypes may be consider relevant and independent factors of toxicity in adjuvant anthracycline- based treatment of breast cancer.
Export Options
About this article
Cite this article as:
R. Zarate , S. Gonzalez-Santiago , E. Bandres , R. Morales , J. Salgado , A. Gomez , E. Aranda and J. Garcia-Foncillas , GSTP1 and MTHFR Polymorphisms Are Related with Toxicity in Breast Cancer Adjuvant Anthracycline-Based Treatment, Current Drug Metabolism 2007; 8 (5) . https://dx.doi.org/10.2174/138920007780866780
DOI https://dx.doi.org/10.2174/138920007780866780 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside
Current Respiratory Medicine Reviews Applications of Nanosystems to Anticancer Drug Therapy (Part I. Nanogels, Nanospheres, Nanocapsules)
Recent Patents on Anti-Cancer Drug Discovery Do Chromatin Interaction Networks Radiate Pathogenic Contagion in the Genome?
Epigenetic Diagnosis & Therapy (Discontinued) Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Reviews on Recent Clinical Trials Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
Current Cancer Drug Targets Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Current Topics in Medicinal Chemistry Genetic Polymorphisms in the Growth Hormone Receptor: Impact on Growth Response and Disease Susceptibility
Current Pharmacogenomics and Personalized Medicine Non-viral Delivery Systems for Breast Cancer Gene Therapy
Current Gene Therapy Anti-Infective Protective Properties of S100 Calgranulins
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Current Drug Discovery Technologies In the Crosshairs: NF-κB Targets the JNK Signaling Cascade
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
Current Cancer Drug Targets Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Probing Multidrug Resistance P-glycoprotein Transporter Activity with SPECT Radiopharmaceuticals
Current Topics in Medicinal Chemistry Is it Possible to Reduce the Incident of Colorectal Cancer by Modifying Diet and Lifestyle?
Current Cancer Therapy Reviews SCF E3 Ubiquitin Ligases as Anticancer Targets
Current Cancer Drug Targets In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer
Current Drug Research Reviews